Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (896)	6/14/1998 9:03:00 AM
From: billy d	Read Replies (1) \| Respond to of 10280

I personally feel that the patent overlap issue with Hoechst will be something the market will react to quite strongly. On the day it was announced the street bashed SEPR believing that a patent problem could effect the majority of their pipeline. Should SEPR win this dispute (which I believe they will) the stock should respond with great vigor to the upside. This is an issue I believe the street is looking at carefully. IMHO these disputes can be a good thing for SEPR as each one that is resolved in their favor only tightens their stronghold on these new compounds. I also read in Barrons last week that Lilly is working on their own form of improved Prozac. They are combining Prozac with one of their anti-psychotic drugs. I don't believe this will speed up wash out time ie. SEPR's version. Any thoughts?